The majority of tuberculosis (TB) patients include non-pulmonary sites of pleural effusion. People in the average culture don't know how to handle emotional situations. Tuberculous pleurisy is infamously hard to detect since the symptoms and tests used to diagnose it are not very specific, and the disease progresses slowly. Despite extensive searching, no evidence of tuberculous pleural fluid had been identified. One possible way to differentiate pleural effusions (TPEs) from malignant pleural effusions (MPEs) is to test the fluid for the enzyme adenosine deaminase (ADA). In terms of differential diagnosis, it is not clear how to differentiate between high-ADA MPE and high-ADA TPE. Two different ratios will be used to compare groups of patients: one with pleural effusion caused by tuberculosis and another with other reasons. These ratios are pleural fluid ADA/serum CRP and pleural fluid LDH/ADA. This is why an integrated strategy and reliable biomarkers are essential. When it comes to diagnosing TP, adenosine deaminase (ADA) is the the biomarker of choice due to its excellent specificity and sensitivity (over 90%). Malignant pleural effusion, to benign pleural effusion (TP), is characterised by a lower level of ADA in patients. However, lymphocyte predomination makes this differentiation challenging.The use of ADA in pleural punctate enables the quick, straightforward, efficient, and cost-effective identification of tuberculous pleurisy as the cause of pleural effusion. Many studies have shown that adverse drug reactions (ADAs) are an integral aspect of monitoring tuberculosis (TB) treatment follow-up. Everyone who had pleural effusion had a thoracentesis performed, and we utilised Light's criteria to figure out if the fluid was transudative or exudative. We announced our predictions for the sensitivity, specificity, positivity predictive accuracy, and negative predictive value of the ADA, CRP, and L/N ratio.